文献速递免疫规划卫生政策与健康促进

在五个欧洲数据库中分析COVID-19疫苗与心肌炎关联时四种自身对照研究设计的比较

A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
PubMed 文献 · Vaccine · 2024-04-05

本研究利用五个欧洲数据库(西班牙BIFAP、FISABIO VID、SIDIAP,意大利ARS-Tuscany,英国CPRD Aurum)的数据,纳入2020年9月1日至各国数据截止期间发生心肌炎且接种过COVID-19疫苗的1757例病例,比较了四种自身对照设计(接种前对照窗口的SCRI、接种后对照窗口的SCRI、标准SCCS、扩展SCCS)在评估事件依赖暴露假设违反所致偏倚方面的表现。结果显示,对于辉瑞疫苗第一剂,两种SCRI和扩展SCCS结果与无效效应一致,而标准SCCS提示有害效应;对于第二剂,所有设计均显示有害关联,效应量相对相似。

要点

  • 辉瑞疫苗第一剂:两种SCRI和扩展SCCS结果与无效效应一致,标准SCCS提示有害效应。
  • 辉瑞疫苗第二剂:所有设计均显示有害关联,效应量相对相似。
  • 莫德纳疫苗第二剂:所有设计结果均与有害效应一致。

核心结论

  • 在COVID-19疫苗与心肌炎已知关联的背景下,两种SCRI和两种SCCS产生了大体可比的结果,可能是因为事件依赖暴露假设的违反有限。

研究设计与样本

  • 使用五个欧洲数据库(西班牙BIFAP、FISABIO VID、SIDIAP;意大利ARS-Tuscany;英国CPRD Aurum)转换为ConcePTION通用数据模型,纳入2020年9月1日至各国数据可用终点之间发生心肌炎且接种COVID-19疫苗的个体,共1757例心肌炎病例。

主要发现

  • 辉瑞疫苗第一剂:两种SCRI和扩展SCCS结果与无效效应一致,标准SCCS提示有害效应。
  • 辉瑞疫苗第二剂:所有设计均显示有害关联,SCRI前对照=1.99(1.40-2.82),SCRI后对照=2.13(95%CI 1.43-3.18),标准SCCS=1.79(95%CI 1.31-2.44),扩展SCCS=1.52(95%CI 1.08-2.15)。
  • 对日历时间进行调整未改变这些结论。
  • 使用所有设计的结果也与莫德纳疫苗第二剂后的有害效应一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to assess the possible extent of bias due to violation of a core assumption (event-dependent exposures) when using self-controlled designs to analyse the association between COVID-19 vaccines and myocarditis. METHODS: We used data from five European databases (Spain: BIFAP, FISABIO VID, and SIDIAP; Italy: ARS-Tuscany; England: CPRD Aurum) converted to the ConcePTION Common Data Model. Individuals who experienced both myocarditis and were vaccinated against COVID-19 between 1 September 2020 and the end of data availability in each country were included. We compared a self-controlled risk interval study (SCRI) using a pre-vaccination control window, an SCRI using a post-vaccination control window, a standard SCCS and an extension of the SCCS designed to handle violations of the assumption of event-dependent exposures. RESULTS: We included 1,757 cases of myocarditis. For analyses of the first dose of the Pfizer vaccine, to which all databases contributed information, we found results consistent with a null effect in both of the SCRI and extended SCCS, but some indication of a harmful effect in a standard SCCS. For the second dose, we found evidence of a harmful association for all study designs, with relatively similar effect sizes (SCRI pre = 1.99, 1.40 - 2.82; SCRI post 2.13, 95 %CI - 1.43, 3.18; standard SCCS 1.79, 95 %CI 1.31 - 2.44, extended SCCS 1.52, 95 %CI = 1.08 - 2.15). Adjustment for calendar time did not change these conclusions. Findings using all designs were also consistent with a harmful effect following a second dose of the Moderna vaccine. CONCLUSIONS: In the context of the known association between COVID-19 vaccines and myocarditis, we have demonstrated that two forms of SCRI and two forms of SCCS led to largely comparable results, possibly because of limited violation of the assumption of event-dependent exposures.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Schultze A, Martin I, Messina D, et al. A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases. Vaccine. 2024. PMID: 38580517. doi:10.1016/j.vaccine.2024.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。